European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

DNA replication at the heart of cell fate decisions and cancer development

Descripción del proyecto

El papel de la replicación del ADN en el destino celular

La duplicación precisa del genoma mediante replicación del ADN puede verse dificultada por diversas tensiones, con consecuencias funestas para la integridad del genoma y el destino celular. El equipo del proyecto RepliFate, financiado por las Acciones Marie Skłodowska-Curie, tiene como objetivo investigar los mecanismos por los cuales la replicación del ADN afecta al destino celular, además de poder provocar cáncer y otras enfermedades. En el marco del proyecto, se ofrecerá formación a investigadores europeos y se generarán conocimientos fundamentales sobre el proceso de transformación maligna. La identificación de agentes clave en la replicación del ADN impulsará futuros esfuerzos en el diseño de tratamientos antineoplásicos innovadores.

Objetivo

RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity.

RepliFate will investigate the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent malignant transformation. We will put DNA replication at the center stage as the driver of these processes and not a mere bystander, using recent technological to better understand the role of DNA replication as a determinant of cell fate and cancer. RepliFate links academia with industry and society and will provide new opportunities for innovation in one of the main societal challenges in human health, cancer. The scientific roots of RepliFate are set on the Horizon Europe Mission Cancer objectives Understand and Optimise. We will pave the way for the development of innovative cancer treatments exploring the links between DNA replication and cell fate, the immune response and unscheduled cell proliferation.

RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. Putting the focus on the fellows, we have combined our expertise to create an outstanding training program with the objective to generate leaders in the field with independent and out-of-the-box views to drive the knowledge of basic science to applications that will improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.

Coordinador

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Aportación neta de la UEn
€ 755 913,60
Dirección
CALLE SERRANO 117
28006 Madrid
España

Ver en el mapa

Región
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo de actividad
Research Organisations
Enlaces
Coste total
Sin datos

Participantes (7)

Socios (13)